Lymphoproliferative disorders

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
목요일, 4월 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
목요일, 3월 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Retrieved on: 
수요일, 1월 31, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Rituximab, Survival, European, EBV, Graft-versus-host disease, MHRA, The Lancet, Patient, FDA, EMA, SOT, Cytokine release syndrome, Society, ATRA, ASH, HCT, Cancer, BLA, Lymphoproliferative disorders, Epstein–Barr virus

22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).

Key Points: 
  • 22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).
  • The median duration of response was 23.0 months and the median overall survival was 18.4 months.
  • These interim data were previously presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
  • All this resonates perfectly with our purpose ‘every time we care for a single person, we make the whole world better,’” said Núria Perez-Cullell, Director of Medical Affairs, Patients & Consumers at Pierre Fabre Laboratories.

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Medical Subject Headings, Diarrhea, Marketing, Agency, INN, Fever, Immune system, Fatigue, Constipation, Infection, Lymph, Hypotension, Virus, Bone marrow, Graft-versus-host disease, International, PTLD, Nasal congestion, Disease, Bone pain, Nausea, Language, Lymphoproliferative disorders, Cancer, Liver, Hyponatremia, Rash, Neutrophil, Appetite, Observation, European Medicines Agency, Transplant, Hypoxia, Select, Cell, Patient, Human, Safety, Dehydration, Anemia, Alkaline phosphatase, IIA, Epstein–Barr virus, Medical device

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Retrieved on: 
수요일, 12월 20, 2023
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, Partnership, Food, FDA, PTLD, Trial of the century, Lymphoproliferative disorders, Biologics license application, Cancer, ATRA, USD, EBV, Patient, CD19, Epstein–Barr virus, BLA, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).
  • Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.
  • In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.
  • Substantially all tab-cel manufacturing, clinical, and regulatory activities are planned to transition from Atara to Pierre Fabre Laboratories at the time of BLA transfer.

Largest International Assembly on Chronic Lymphocytic Leukemia (CLL) Raises Curtain on 20th Biennial Meeting in Boston, Massachusetts

Retrieved on: 
화요일, 10월 3, 2023
CLL, International Workshop on Lung Health, Abstract, Partnership, Lymphoproliferative disorders, Epidemiology, Court of general sessions, Research, Genomics, Doctor of Philosophy, BTK, Proteomics, Hynes Convention Center, Harvard Medical School, Medicine, Metabolism, MD, Patient, Physician, Hematology, XX, Diagnosis, Chronic lymphocytic leukemia, Leukemia, Health, Social media, Disease, Dana–Farber Cancer Institute, Medical device, Veterinary medicine

BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts. Founded in 1979, iwCLL is the world's leading member-driven organization dedicated to the field of CLL and related lymphoproliferative disorders, bringing together leaders from scientific research, clinical medicine, and the pharmaceutical and biotechnology industries.

Key Points: 
  • BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts.
  • The International Workshop on Chronic Lymphocytic Leukemia hosts its 20th biennial meeting in Boston on Oct. 6-9, 2023.
  • "Recent data from both the laboratory and clinic have reignited the CLL community's enthusiasm and dedication toward finding a cure.
  • The 4-day event will begin on Friday with a Young Investigator Meeting, applicable for individuals early in their hematology careers.

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Retrieved on: 
화요일, 8월 8, 2023
Lymphoma, PTCL, Peripheral T-cell lymphoma, Hematopoietic stem cell transplantation, ASH, Angioimmunoblastic T-cell lymphoma, Lymphoproliferative disorders, Creatinine, DLBCL, Thomas Jefferson University, Aes, Valganciclovir, Constipation, Oncology, Histone deacetylase inhibitor, B-cell lymphoma, Bone marrow, Patient, Division, American Society of Hematology, Data, SAN, PTLD, PTCL-NOS, Cytopenia, Nausea, Paper, CRS, Therapy, Society, ORR, Disease, Vaccine, Pharmaceutical industry, Hematology

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the publication of clinical data from an open-label, multicenter, Phase 1b/2 study of Nana-val in 55 patients with R/R EBV+ lymphoma in Blood Advances. Results showed complete responses (CRs) achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers: peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disease (PTLD). This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here.

Key Points: 
  • This paper titled, “Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study,” can be found here .
  • The published paper includes an additional 10-month follow-up period, which demonstrated durable response durations across multiple EBV+ lymphoma subtypes.
  • Overall, trial participants received a median of two prior therapies before entering the trial, with 75% (41/55) being refractory to their last therapy.
  • Initial data from the Nana-val Phase 1b/2 clinical trial were previously presented at the 2021 American Society of Hematology (ASH) Annual Meeting .

ISHLT 2023 Annual Meeting Awards Showcase Advances in Treatment of Advanced Heart and Lung Disease

Retrieved on: 
금요일, 6월 2, 2023
Abstract, Society, University, UT, Lymphoproliferative disorders, Lung transplantation, Cancer, University of New South Wales, Research, Transplant, GA, University of Utah, Philip, Asian Americans Advancing Justice Southern California, Journal, Patient, Microcirculation, LVEDD, Heart failure, Stanford University School of Medicine, Heart transplantation, LVAD, Great Ormond Street Hospital, MCS, International Society, Dentistry, Medical device, Nursing, Birth control, Heart, Stanford University

Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.

Key Points: 
  • Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.
  • All conference abstracts are available in a special supplement to the Journal of Heart and Lung Transplantation’s April 2023 issue.
  • The team evaluated donor characteristics associated with heart acceptance in the USA and applied modern analytic methods to improve the prediction of heart acceptance.
  • Purpose: Heart transplant remains the gold standard treatment for patients with advanced heart failure.

EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases

Retrieved on: 
월요일, 4월 3, 2023
Vaccine, GMP, Human, Epstein–Barr virus, Genetics, Lymphoproliferative disorders, EBV, CSO, ME/CFS, Immunity, EST, CMO, Multiple sclerosis, Incidence, Infectious mononucleosis, Chronic fatigue syndrome, DSM-IV codes, PTLD, Immune system, Cancer, Walter, Washington Convention Center, Virus-like particle, Convention center, Disease

The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the

Key Points: 
  • The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the
    Walter E. Washington Convention Center in Washington, DC.
  • The first candidate, named EBV-001, is based on non-infectious EBV-derived virus-like particles (VLPs).
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • As infectious mononucleosis is a known risk factor for multiple sclerosis, there is great hope that our vaccine may also reduce the incidence of this chronic neurodegenerative autoimmune disease.”

Asparaginase Global Market Report 2022: Rising Incidences of Leukemia and Increasing Usage Application Driving Growth - ResearchAndMarkets.com

Retrieved on: 
수요일, 10월 19, 2022
Pharmaceutical, Health, Oncology, Biomedical engineering, Leukemia, Transport, Growth, Population, Ammonia, Escherichia coli, Degenerative disease, CAGR, Asparaginase, Research, Food industry, Acute leukemia, R, Geography, Industry, Incidence, Nanomedicine, Food, T-Cell Acute Lymphoblastic Leukemia, Lymphoma, Allergy, COVID-19, Lymphoproliferative disorders, Pet, Fine chemical, Pharmaceutical industry

The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.

Key Points: 
  • The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.
  • The rising incidence of leukemia and the significant growth in the pharmaceutical and food industry are the major factors boosting the market.
  • Thus, an increasing population is contributing to the expansion in the food and pharmaceutical industries, driving the global asparaginase market.
  • The increasing demand for E. coli asparaginase in the cancer treatment and food processing industry promotes the growth of the global asparaginase market.